B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)活性蛋白
Active B-Lymphocyte Activation Antigen B7-1 (LAB7-1)
CD80; CD28LG; CD28LG1; BB1; B7-1 Antigen; T-lymphocyte activation antigen CD80; CTLA-4 counter-receptor B7.1
- 編號UAPB386Hu61
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)5.4
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 552 ¥ 1380 ¥ 2760 ¥ 8280 ¥ 20700
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
B-Lymphocyte Activation Antigen B7-1 (CD80) is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy. CD80 can combine with CD86, thus, a binding ELISA assay was conducted to detect the association of recombinant human CD80 with recombinant human CD86. Briefly, biotin-linked recombinant human CD80 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to CD86-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μl stop solution to the wells and read at 450 nm immediately. The binding activity of recombinant human CD80 and recombinant human CD86 was shown in Figure 1, the EC50?for this effect is 0.412 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UEPB386Hu61 | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB386Hu61 | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAB386Hu06 | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)多克隆抗體 | WB |
| UPAB386Hu01 | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)多克隆抗體 | WB; IHC; ICC; IP. |
| UFAB386Hu01 | 抗B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)多克隆抗體 | FCM |
| USEB386Hu | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB386Hu | B-淋巴細(xì)胞激活抗原B7-1(LAB7-1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| BioMed Research International | Predictability of Urinary CD80 in the Relapse of Primary Nephrotic Syndrome [pubmed:28951877] |
